A drug-screening platform for ALS

This shows a control iPSC-derived motor neuron (left) and a motor neuron derived from ALS patient-specific iPSC (right). Credit: Haruhisa Inoue's Laboratory, CiRA, Kyoto University

A research group at the Center for iPS Cell Research and Application (CiRA) at Japan's Kyoto University has successfully recapitulated amyotrophic lateral sclerosis (ALS)-associated abnormalities in motor neurons differentiated from induced pluripotent stem cells (iPSCs) obtained from patients with familial ALS, a late-onset, fatal disorder which is also known for Lou Gehrig's disease. In a drug screening assay using the disease model, the team further found that the chemical compound anacardic acid can rescue some ALS phenotypes in vitro.

In a study published online in Science Translational Medicine, Associate Professor Haruhisa Inoue and his team generated motor neurons from iPSCs derived from three ALS patients with mutations in Tar DNA-binding protein-43 (TDP-43). The motor neurons showed cellular phenotypes including vulnerability to stress, shorter neurites, and cytosolic aggregates similar to those seen in postmortem tissues from ALS patients. The team also found that TDP-43 mRNA was upregulated in the ALS motor neurons, which means that TDP-43 autoregulation was disturbed, and that TDP-43 protein in detergent-insoluble form aggregated with the splicing factor SNRPB2 in the nucleus, perturbing RNA metabolism. These findings shed light on the mechanism of disease onset.

Using the motor neurons as a , the researchers discovered that the anacardic acid can rescue the abnormal ALS motor neuron phenotypes. For example, when anacardic acid, a histone acetyltransferase inhibitor, was sprinkled on the motor neurons, TDP-43 was decreased, and the length of the increased.

''Our work represents an initial stage of drug screening for ALS using patient-specific iPSCs. TDP-43 is not only relevant to familial ALS but also to sporadic ALS, which represents the majority of ALS cases,'' said Inoue, a principal investigator at CiRA who is also one of research directors for the CREST research program funded by the Japan Science and Technology Agency. ''We will continue to work on ALS patient-specific iPSCs in order to help develop new drug seeds and candidates.''

More information: Egawa et al. "Drug Screening for ALS Using Patient-Specific Induced Pluripotent Stem Cells" Science Translational Medicine.

add to favorites email to friend print save as pdf

Related Stories

OHSU discovery may lead to new treatment for ALS

Jul 18, 2012

Researchers at Oregon Health & Science University School of Dentistry have discovered that TDP-43, a protein strongly linked to ALS (Amyotrophic Lateral Sclerosis) and other neurodegenerative diseases, appears to activate ...

Recommended for you

Stem cells faulty in Duchenne muscular dystrophy

58 minutes ago

Like human patients, mice with a form of Duchenne muscular dystrophy undergo progressive muscle degeneration and accumulate connective tissue as they age. Now, researchers at the Stanford University School of Medicine have ...

Here's how the prion protein protects us

5 hours ago

The cellular prion protein (PrPC) has the ability to protect the brain's neurons. Although scientists have known about this protective physiological function for some time, they were lacking detailed knowledge ...

Regulation of maternal miRNAs in early embryos revealed

6 hours ago

The Center for RNA Research at the Institute for Basic Science (IBS) has succeeded in revealing, for the first time, the mechanism of how miRNAs, which control gene expression, are regulated in the early embryonic stage.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.